Q-omics provides the consensus-scored FOXD4L5 profile across patient tissues and cancer cell-line models. FOXD4L5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, FOXD4L5 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, FOXD4L5 RNA expression shows 6,574 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, PAAD, and TGCT as cancer lineages where FOXD4L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXD4L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXD4L5 survival associations across molecular data types. FOXD4L5 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXD4L5 RNA expression–survival associations across cancer types. High FOXD4L5 expression shows unfavorable associations in DLBC, COAD, KICH and UCEC, but favorable associations in CESC and UCS. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for FOXD4L5 RNA expression.
This table summarizes FOXD4L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FOXD4L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXD4L5 shows lower tumor expression in BRCA and KICH and higher tumor expression in PAAD and STAD. The PAAD box plot shows higher FOXD4L5 RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p = .002).
This table shows molecular features associated with FOXD4L5 in patient tissues and cancer cell lines. In patient samples, FOXD4L5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXD4L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
